Presentations & Publications
p27 small molecule inhibitors for CDK4/6i-resistant metastatic breast cancer (mBC)
IpY.20: Innovative strategies for post-CDK estrogen receptor (ER)+ metastatic breast cancer (mBC)
Drugging p27 to inhibit CDK2/4/6 together
Triple CDK2/4/6 inhibition via p27 modulation: A novel approach to targeting cell cycle dysregulation
Concarlo in the News
Biotech TV: Stacy Blain is the Founder and CEO of Concarlo Therapeutics, which is the first company to target CDK4/6-driven cell proliferation and CDK2-driven resistance
Anyo Labs Collaboration with Concarlo Therapeutics
AFCR Announces Winner of the 2024 BRACE Award Venture Competition
Concarlo Therapeutics Presents Novel Therapeutic Approach for ER+ Metastatic Breast Cancer Targeting the CDK Pathway
Webinars & Talks
2024 BRACE Award Venture Competition- Concarlo Therapeutics
Concarlo Therapeutics at Evercore ISI 2024 Emerging Biotech Conference
Beyond Biotech podcast 24: Concarlo Therapeutics
The academic to founder pipeline with Dr. Stacy Blain from Concarlo Therapeutics
Awards
“The reward for work well done is the opportunity to do more”
—Jonas Salk
Winner of 2025 TiE SoCal Women Founders
Pitch Competition
Top Therapeutic Company at Aquillius’ 2025 Innovation in Women’s Health Pitch Showcase
The 50 Most admired companies: CIO Bio
Top 100 entreprenuers: Alumni List
Top Biotech Startup 2022
Awarded by: Life Sciences Review
